Menlo Park, CA (PRWEB) December 17, 2014 Gene synthesis and bioengineering company DNA2.0 Inc. announces today that it has entered into a technology access and services agreement with Archer Daniels Midland Company (ADM) to apply DNA2.0s proprietary protein engineering technology, known as ProteinGPS to ADMs industrial enzyme engineering process. We are extremely excited that the global leader ADM has adopted our ProteinGPS engineering platform. This proprietary bioengineering technology has now been validated through many scientific collaborations, peer-reviewed scientific publications and strong underlying IP. It is exciting to see broad adoption of the technology with partners ranging from Fortune 500 companies to small startups, and in commercial fields ranging from chemical biocatalysis to therapeutic proteins, said Claes Gustafsson, DNA2.0s Chief Commercial Officer. Our ProteinGPS technology allows us to engineer any measurable biological function, such as activity, stability, immunogenicity, substrate specificity, manufacturability, etc., using only a few hundred samples in real commercial endpoint application assays. ADM is eager to work with DNA2.0 to enhance and expand our R&D technology portfolio in the area of protein engineering. We truly appreciate DNA2.0s GPS technology platform and DNA2.0s expertise in bioengineering, and we look forward to a productive collaboration in producing the most efficient enzymes … Continue reading →